Resources

An overview of MSF’s programmatic use and clinical research with new TB treatment regimens.

Purpose: To evaluate the use of Bayesian adaptive randomization for clinical trials of new treatments for multidrug-resistant tuberculosis.

This MSF Access Campaign report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.

We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.

This report was produced with endTB's support.

This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.